News
Nurix Therapeutics shows strong BTK degrader data and key pharma ties, with risks but solid long-term potential. Find out why ...
Robinhood posted strong Q1 growth and is expanding into new products, but valuation and regulatory risks cloud the outlook. Find out why HOOD stock is a hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback